Please assess the completion status of the following clinical trial:

Trial Title: TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria Includes:~* Drusen \> 63 mm~* Choroidal neovascularization under the fovea (Predominantly Classic, Minimally Classic, and Occult lesions acceptable)~* Greatest linear dimension (GLD) of entire lesion \< 5400 µm (no reading center confirmation required)~* ETDRS best corrected visual acuity of 20/40 - 20/320 (73 - 24 letter score)~* Total area of lesion must \< 9 MPS DA~* 0-3 intravitreal injections of anti-VEGF monotherapy within 6 months of randomization with continuing evidence of exudative activity confirmed by FA or OCT within 4-8 weeks after the last injection~Exclusion Criteria Includes:~* Oral steroid use within 6 months~* Prior complications from steroid therapy~* Prior stroke, myocardial infarction, or end-stage malignancy~Study Eye Exclusion Criteria~* Geographic atrophy or fibrosis under the fovea~* Fibrosis, hemorrhage, pigment epithelial detachments and other hypofluorescent lesions obscuring more than 50% of total lesion~* Prior treatment with verteporfin within 12 months~* IOP is \>25 mmHg and the participant is on Cosopt~* Intraocular surgery within 6 weeks~* Prior vitrectomy~* Peribulbar steroid injection within 6 months~* Poor reactions to topical or periocular steroid treatment including elevated IOP

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).